Symbol | Exchange | Currency |
|---|
Investing.com – U.S. stocks were higher after the close on Wednesday, as gains in the Consumer Services, Technology and Consumer Goods sectors led shares higher. At the close in...
Investing.com – U.S. stocks were higher after the close on Wednesday, as gains in the Technology, Oil & Gas and Industrials sectors led shares higher. At the close in NYSE, the...
Gainers: XBIO +151%. ABIL +79%. ASCMA +48%. SBOT +38%. HRTX +33%. RYTM +23%. BNED +20%. BOXL +17%. BFR +16%. AVLR +14%. Losers: NVIV -46%. GEVO -27%. NAKD -21%. CLPS -20%....
Agios Pharmaceuticals Inc. (NASDAQ:AGIO) incurred third-quarter 2018 loss of $1.63 per share, narrower than the Zacks Consensus Estimate of a loss of $1.69 but wider than the...
Acorda Therapeutics, Inc. (NASDAQ:ACOR) announced third-quarter 2018 earnings per share of 17 cents, beating the Zacks Consensus Estimate of 15 cents. However, the figure...
Caladrius Biosciences Inc (NASDAQ:CLBS) is developing cell therapy (CT) products that extract, expand and bolster a patient’s own (autologous) immune cells to treat diseases....
Caladrius Biosciences, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery, development and commercialization of cell therapies designed to reverse disease and promote the regeneration of damaged tissue. The Company is developing therapeutics based on the characteristics of naturally occurring CD34+ cells and their ability to stimulate the growth of new microvasculature. The Company’s product candidates include CLBS16, CLBS12 and CLBS201. The CLBS16 (XOWNA) is an experimental regenerative medicine that is being studied in a Phase IIb study (the FREEDOM trial) in the United States for the treatment of coronary microvascular dysfunction. The CLBS12 (HONEDRA) is an experimental regenerative medicine being studied in Japan for the prevention of serious adverse consequences of critical limb ischemia. The CLBS201 is an experimental regenerative medicine designed to assess the safety and efficacy of CD34+ cell therapy as a treatment for diabetic kidney disease.
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Strong Buy | Strong Buy | Buy | Buy | Sell |
| Technical Indicators | Sell | Sell | Strong Buy | Strong Buy | Strong Sell |
| Summary | Neutral | Neutral | Strong Buy | Strong Buy | Strong Sell |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 308.08 | 308.49 | 301.30 | +7.89 | +2.63% | 2.30M | NYSE | |||
| 49.44 | 49.48 | 48.68 | +0.87 | +1.79% | 2.88M | NASDAQ | |||
| 8.37 | 8.47 | 8.16 | +0.24 | +2.95% | 6.64M | NYSE | |||
| 4.44 | 4.47 | 4.44 | 0.000 | 0.00% | 0.00 | NYSE | |||
| 3.60 | 3.65 | 3.54 | +0.080 | +2.27% | 10.10M | NYSE | |||
| 32.74 | 32.75 | 31.69 | +0.89 | +2.81% | 4.93M | NYSE | |||
| 1.085 | 1.10 | 1.01 | +0.0650 | +6.37% | 306.83K | NYSE | |||
| 46.26 | 46.28 | 45.16 | +1.36 | +3.03% | 1.89M | NYSE | |||
| 1.205 | 1.23 | 1.19 | -0.0050 | -0.41% | 2.57M | NYSE | |||
| 43.51 | 43.66 | 43.24 | -0.11 | -0.25% | 5.55M | NYSE | |||
| 50.90 | 51.04 | 49.74 | -0.20 | -0.39% | 3.16M | NYSE | |||
| 50.11 | 50.39 | 48.55 | +1.82 | +3.77% | 25.57M | NYSE | |||
| 0.0006 | 0.0006 | 0.0006 | 0.00000 | 0.00% | 0.00 | OTC Markets | |||
| 81.24 | 81.24 | 80.44 | +0.54 | +0.67% | 1.27M | NYSE | |||
| 128.20 | 128.52 | 126.71 | +1.21 | +0.95% | 768.09K | NYSE |